Manoel Barros Bertolo Selected Research

Rheumatoid Vasculitis

6/2015	The role of KIR2DL3/HLA-C*0802 in Brazilian patients with rheumatoid vasculitis.
5/2012	Association of HLA-DRB5*01 with protection against cutaneous manifestations of rheumatoid vasculitis in Brazilian patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manoel Barros Bertolo Research Topics

Disease

10	Rheumatoid Arthritis 11/2021 - 01/2011
4	Infections 08/2019 - 03/2011
4	Neoplasms (Cancer) 05/2015 - 03/2011
2	Rheumatoid Vasculitis 06/2015 - 05/2012
2	Tuberculosis (Tuberculoses) 05/2015 - 03/2011
2	Diabetes Mellitus 08/2012 - 05/2012
2	Arthritis (Polyarthritis) 06/2011 - 05/2011
2	Polyarteritis Nodosa (Periarteritis Nodosa) 01/2009 - 06/2004
1	Latent Tuberculosis 07/2015
1	Bacterial Infections (Bacterial Infection) 05/2015
1	Hematologic Neoplasms (Hematological Malignancy) 05/2015
1	Rheumatic Diseases (Rheumatism) 05/2015
1	Human Influenza (Influenza) 02/2013
1	Tetanus 02/2013
1	Chickenpox 02/2013
1	Hepatitis A (Hepatitis, Infectious) 02/2013
1	Hereditary Complement Deficiency Diseases 02/2013
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2013
1	Pulmonary Arterial Hypertension 01/2013
1	Systemic Scleroderma (Systemic Sclerosis) 01/2013
1	Hypertension (High Blood Pressure) 08/2012
1	Osteoporosis 08/2012
1	Atherosclerosis 08/2012
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2012
1	Venous Thrombosis (Deep-Vein Thrombosis) 08/2012
1	Microscopic Polyangiitis 01/2009
1	Eosinophilia 04/2004

Drug/Important Bio-Agent (IBA)

3	Biological ProductsIBA 08/2019 - 03/2011
3	Pharmaceutical PreparationsIBA 05/2018 - 03/2011
2	Antirheumatic Agents (DMARD)IBA 08/2019 - 02/2013
2	VaccinesIBA 05/2015 - 02/2013
2	AntibodiesIBA 02/2013 - 01/2011
2	Anti-Citrullinated Protein AntibodiesIBA 05/2011 - 01/2011
2	cyclic citrullinated peptideIBA 05/2011 - 01/2011
1	Janus Kinase InhibitorsIBA 11/2021
1	tofacitinibIBA 11/2015
1	Tuberculin (PPD)IBA 07/2015
1	HLA-C Antigens (HLA-C)IBA 06/2015
1	LigandsIBA 06/2015
1	HLA-DRB1 Chains (HLA DRB1)IBA 06/2015
1	KIR ReceptorsIBA 06/2015
1	Meningococcal Vaccines (Meningococcal Vaccine)IBA 02/2013
1	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 02/2013
1	Hepatitis B Vaccines (Hepatitis B Vaccine)IBA 02/2013
1	BCG Vaccine FDA Link 02/2013
1	Rituximab (Mabthera)FDA Link 02/2013
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 02/2013
1	Papillomavirus Vaccines (HPV Vaccines)IBA 02/2013
1	Immunoglobulins (Immunoglobulin)IBA 02/2013
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2013
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 08/2012
1	Angiotensin Receptor AntagonistsIBA 08/2012
1	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2012
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 08/2012
1	CalciumIBA 08/2012
1	Dietary CalciumIBA 08/2012
1	LDL CholesterolIBA 08/2012
1	Vitamin D FDA LinkGeneric 08/2012
1	HLA-DRB5 Chains (HLA DRB5)IBA 05/2012
1	Illicit Drugs (Recreational Drugs)IBA 05/2012
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2011
1	ametantrone (HAQ)IBA 05/2011
1	Rheumatoid FactorIBA 05/2011
1	1- hydroxy- 5,8- bis(2- ((2- hydroxyethyl)amino)ethylamino)- 9,10- anthracenedioneIBA 05/2011
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 05/2011
1	EpitopesIBA 01/2011
1	Anti-Idiotypic AntibodiesIBA 01/2011
1	Peptides (Polypeptides)IBA 01/2011
1	HLA-DR Antigens (HLA-DR)IBA 01/2009
1	Interleukin-8 (Interleukin 8)IBA 06/2004
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 04/2004

Therapy/Procedure

2	Therapeutics 08/2012 - 06/2011
1	Biological Therapy 05/2015